Trials / Completed
CompletedNCT02395601
A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients With B-Cell Lymphomas
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (estimated)
- Sponsor
- Constellation Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
First in human, open-label, sequential dose escalation and expansion study of CPI-1205 in patients with progressive B-cell lymphomas. CPI-1205 is a small molecule inhibitor of EZH2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CPI-1205 | Small molecule inhibitor of the enzyme EZH2 |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2015-03-23
- Last updated
- 2022-05-18
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02395601. Inclusion in this directory is not an endorsement.